Related Experiment Video
Updated: Feb 24, 2026
03:50
Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
3.0K
[Pharmacotherapy in Patients with Chronic Constipation].
Sang Jin Kim1, Kyung Sik Park1
1Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
Summary
Constipation management in Korea faces challenges due to limited access to advanced treatments like chloride channel inhibitors and certain polyethylene glycols. This review examines available constipation medications in Korea and globally.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Chronic constipation is a prevalent digestive disorder significantly impacting patient quality of life.
- Current therapeutic options for constipation in Korea have limitations.
- Several advanced constipation treatments are not yet available or fully reimbursed in Korea.
Purpose of the Study:
- To assess medications clinically available for managing chronic constipation in Korea.
- To provide a brief overview of globally developed constipation-modulating agents.
- To highlight the current landscape and limitations of constipation pharmacotherapy in the Korean context.
Main Methods:
- Review of clinically available constipation medications in Korea.
- Assessment of global developments in constipation pharmacotherapy.
- Analysis of treatment accessibility and insurance coverage in Korea.
Main Results:
- Chloride channel inhibitors (lubiprostone, linaclotide) are not yet available in Korea.
- Prucalopride and certain polyethylene glycol formulations lack medical insurance coverage in Korea.
- The study identifies available treatment options while acknowledging global advancements.
Conclusions:
- There is a need for expanded access to effective constipation treatments in Korea.
- The review provides a comparative perspective on available and emerging therapies for chronic constipation.
- Understanding global trends is crucial for improving constipation management in Korea.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
959
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
959
01:17Drugs for Treatment of Diarrhea-Predominant IBS
781
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
781
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
646
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
646
01:20Drugs Affecting GI Tract Motility: Other Laxatives
1.2K
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.2K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
837
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
837